New Mexico Educational Retirement Board Buys 800 Shares of Edwards Lifesciences Corp (EW)

New Mexico Educational Retirement Board boosted its stake in Edwards Lifesciences Corp (NYSE:EW) by 4.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,260 shares of the medical research company’s stock after acquiring an additional 800 shares during the period. New Mexico Educational Retirement Board’s holdings in Edwards Lifesciences were worth $2,284,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Victory Capital Management Inc. increased its position in Edwards Lifesciences by 4.6% in the 3rd quarter. Victory Capital Management Inc. now owns 557,773 shares of the medical research company’s stock valued at $60,969,000 after acquiring an additional 24,399 shares during the period. Korea Investment CORP increased its position in Edwards Lifesciences by 144.5% in the 3rd quarter. Korea Investment CORP now owns 355,683 shares of the medical research company’s stock valued at $38,880,000 after acquiring an additional 210,200 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in Edwards Lifesciences by 53.3% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock valued at $1,418,000 after acquiring an additional 4,170 shares during the period. Oakbrook Investments LLC increased its position in Edwards Lifesciences by 25.7% during the 3rd quarter. Oakbrook Investments LLC now owns 19,050 shares of the medical research company’s stock worth $2,082,000 after purchasing an additional 3,900 shares during the period. Finally, ING Groep NV increased its position in Edwards Lifesciences by 41.2% during the 3rd quarter. ING Groep NV now owns 22,905 shares of the medical research company’s stock worth $2,504,000 after purchasing an additional 6,684 shares during the period. Hedge funds and other institutional investors own 81.11% of the company’s stock.

In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $127.24, for a total value of $674,372.00. Following the sale, the vice president now owns 24,908 shares of the company’s stock, valued at approximately $3,169,293.92. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $106.86, for a total value of $3,515,694.00. The disclosure for this sale can be found here. Insiders have sold a total of 205,530 shares of company stock worth $24,163,915 in the last three months. Corporate insiders own 2.13% of the company’s stock.

Shares of Edwards Lifesciences Corp (NYSE:EW) opened at $133.82 on Friday. The company has a market capitalization of $28,500.97, a P/E ratio of 35.44, a PEG ratio of 1.99 and a beta of 0.63. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.81. Edwards Lifesciences Corp has a 52 week low of $89.20 and a 52 week high of $138.48.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.03. The business had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The company’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.75 EPS. research analysts expect that Edwards Lifesciences Corp will post 4.49 earnings per share for the current fiscal year.

Edwards Lifesciences announced that its board has initiated a share repurchase plan on Thursday, December 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Several research firms have issued reports on EW. Cowen reiterated a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences in a research report on Thursday, February 1st. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $145.00 target price on the stock in a research report on Thursday, February 8th. JMP Securities boosted their target price on Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a research report on Friday, February 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $155.00 target price on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Finally, Guggenheim reiterated a “buy” rating and set a $162.00 target price on shares of Edwards Lifesciences in a research report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $141.15.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/02/17/new-mexico-educational-retirement-board-buys-800-shares-of-edwards-lifesciences-corp-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply